Johnson & Johnson (JNJ) — Stock Price, Chart & Analysis
Johnson & Johnson (JNJ) is a Healthcare stock currently trading at $269.19, down 0.10% on the day. It carries a market capitalization of $648.72B and a trailing P/E ratio of 31.26. Over the past 52 weeks, JNJ has traded between $175.74 and $281.07. Johnson & Johnson pays a dividend yielding 2.0%. View the live JNJ chart, technical opinion, analyst ratings, fundamentals and latest news below.
Johnson & Johnson (JNJ) key data
| Price | $269.19 |
| Change (today) | -0.10% |
| Previous close | $269.47 |
| Market cap | $648.72B |
| P/E ratio (TTM) | 31.26 |
| EPS (TTM) | $8.61 |
| Dividend yield | 2.0% |
| 52-week high | $281.07 |
| 52-week low | $175.74 |
| Beta | 0.23 |
| Avg. volume | 7.35M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Johnson & Johnson (JNJ)
How much does one share of Johnson & Johnson cost?
As of the latest update, one share of Johnson & Johnson (JNJ) trades at $269.19 (-0.10% today).
What is Johnson & Johnson's market cap?
Johnson & Johnson has a market capitalization of approximately $648.72B.
What is Johnson & Johnson's P/E ratio?
Johnson & Johnson has a trailing price-to-earnings (P/E) ratio of 31.26.
What is Johnson & Johnson's earnings per share (EPS)?
Johnson & Johnson's trailing twelve-month EPS is $8.61.
Does Johnson & Johnson pay a dividend?
Yes — Johnson & Johnson pays a dividend with a yield of 2.0% ($5.36 per share annually).
What is Johnson & Johnson's 52-week trading range?
Over the past year, JNJ has traded between $175.74 and $281.07.
What is the analyst price target for Johnson & Johnson?
The mean analyst price target for Johnson & Johnson is $277.91. This is informational only and not investment advice.
Latest Johnson & Johnson (JNJ) news
- Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet NowNews · Sep 23, 2026
- JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania StudyNews · Sep 22, 2026
- What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For ShareholdersNews · Sep 22, 2026
- Why Is JNJ Stock Beating Rivals That Grow Faster?News · Sep 22, 2026
- What Could Johnson & Johnson (JNJ) Gain From Its New Immunology Push?News · Sep 22, 2026
- J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar winNews · Sep 22, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live JNJ dashboard…